16 results about "Dna targeting" patented technology

The invention relates to the technical field of nucleic acid detection, and discloses a construction method of a PFLAMP-Cas12b one-tube method reaction system based on single-stranded stem loop mediation. The construction method comprises the following steps: designing an LAMP amplification primer; designing an sgRNA sequence of a single-stranded loop region in a targeted LAMP amplification product; and constructing a reaction system containing the LAMP amplification primer, the Cas12b protein, the sgRNA sequence and the fluorescence report probe. A single-chain stem-loop structure formed in an LAMP amplification product is used as a specific activation target of the Cas12b protein, PAM dependence of the Cas12b protein on double-chain DNA targeting in traditional detection is avoided, and the bottleneck that sgRNA design is limited due to lack of natural PAM sites in a highly conserved gene area is effectively overcome; and non-specific background amplification interference induced by artificially introducing a PAM sequence into the primer is eliminated, and the detection accuracy is improved.

To provide a novel RNA targeting system.SOLUTION: The invention relates to CRISPR-Cas system comprising: a) one or more V type CRISPR-Cas polynucleotide sequence including a guide RNA, the guide RNA including a guide sequence coupled to a direct repeat sequence and capable of hybridizing to a target sequence, or one or more nucleotide sequence coding one or more V type CRISPR-Cas polynucleotide sequence; b) a Cpf1 effector protein or one or more nucleotide sequence coding Cpf1 effector protein, in the CRISPR-Cas system, one or more guide sequences can hybridize to the target sequence, the target sequence is positioned at 3' side of a protospacer adjacent motif (PAM), and the guide RNA forms a composite with the Cpf1 effector protein, the CRISPR-Cas system being engineered and not existing in nature.SELECTED DRAWING: None

Provided are lipid nanoparticles (LNPs) and compositions thereof for delivery of nucleic acid molecules, e.g., ribonucleic acid (RNA), into cells, such as primary cells e.g., T cells, or induced cells, e.g., iPSCs and cells differentiated from iPSCs. Also provided are methods for formulating LNPs, and for delivering nucleic acid molecules into cells, primary cells or induced cells using LNP compositions, including in connection with modulating gene expression using DNA targeting systems.

The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR-Cas systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.

To provide novel CRISPR DNA targeting enzymes and systems.SOLUTION: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.SELECTED DRAWING: None

Provided herein are fusion proteins comprising transposase domains and DNA targeting domains. In particular, the DNA targeting domains may be targeted to the lipoprotein A (LPA) gene. Also provided are methods of making the transposase domains and fusion proteins, cells that are modified using the fusion proteins provided herein and methods of treatment using such cells.

The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR-Cas systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.

Disclosed herein are DNA targeting systems that target a regulatory element of a gene within the 15q11-13 locus. Further provided are DNA targeting systems including at least one gRNA and a Cas9 protein, as well as compositions comprising the same. The compositions may be used in methods for treating Prader-Willi Syndrome (PWS) in a subject. The method may include administering to a subject the DNA targeting system.

Provided herein are methods for treating chronic hepatitis B (CHB) infections in human subjects. In some embodiments, the methods involve administering a lipid nanoparticle carrying an epigenetic-modifying DNA targeting system composed of polynucleotides for targeting repression of total Hepatitis B Viral (HBV) transcripts. Also provided is a lipid nanoparticle carrying the polynucleotides.

This disclosure generally relates to transposase domains, in particular, transposase domains comprising amino terminal deletions, as well as transposase domains forming obligate heterodimers and transposase domains comprising DNA targeting domains.

The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.

The disclosure describes novel systems, methods, and compositions for manipulating nucleic acids in a targeted manner. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target the nucleic acids.

Disclosed herein are novel transcription factors for promoting reprogramming of, and / or for direct conversion of, an astrocyte to a neuron. Further provided are polynucleotides encoding the transcription factors, as well as DNA targeting composition to activate expression of the transcription factor. The DNA targeting compositions may include a Cas9 protein or fusion protein, and at least one gRNA. Further provided are methods of treating a neurodegenerative disease or neurodegenerative injury.

The present invention provides a synthetic, modular system for DNA modification as may be employed for genome editing comprising a targeting nucleic acid possessing both DNA targeting ability and ability to bind a recognition module of a modular polypeptide component, where the modular polypeptide component also includes an effector component and a short peptide DNA-binding sequence (DBD) which binds a pre-determined sequence (PBS) in the target. The DBD may preferably be no more than a 15 mer and serves to destabilize the structure of a targeted dsDNA upon binding thereby facilitating the desired DNA modification. The effector component may, for example, be an artificial nickase comprising linked self-assembling peptides thereby providing a complete genome-editing system of advantageous small size for vector delivery to cells.

The invention provides a photosensitizer with a DNA targeting characteristic and application of the photosensitizer as an intracellular drug-resistant bacterium scavenger, and belongs to the technical field of photosensitive antibacterial drugs. The photosensitizer with the DNA targeting characteristic can effectively penetrate through cell membranes and biological membranes of mammals and target DNA of drug-resistant bacteria, can effectively kill the drug-resistant bacteria such as methicillin-resistant staphylococcus aureus under the condition of light source irradiation, and relieves the drug resistance condition of existing antibiotics. Results of the embodiment show that after the TPE-CN is illuminated for 5 minutes, the TPE-CN has a good methicillin-resistant staphylococcus aureus killing effect under the administration concentration of 5-20 [mu] M, and the sterilizing effect on animals is better than that of vancomycin. The invention provides a preparation method of the photosensitizer with the DNA targeting characteristic, and the method is simple to operate and easy to realize industrial batch production.

The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.